Acro Biomedical Co., Ltd.
ACBM · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.02 | -0.20 | -0.01 |
| FCF Yield | -61.11% | -0.25% | -0.05% | 0.12% |
| EV / EBITDA | -2.28 | 0.00 | -17.03 | 0.00 |
| Quality | ||||
| ROIC | 15.74% | 4,299.41% | -3,099.02% | -1,108.36% |
| Gross Margin | 0.00% | 0.00% | 21.34% | 21.67% |
| Cash Conversion Ratio | 0.87 | 0.00 | 0.01 | -0.04 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -1.45% | 83.59% |
| Free Cash Flow Growth | -137.55% | 89.53% | -149.27% | 250.07% |
| Safety | ||||
| Net Debt / EBITDA | -0.70 | 0.00 | -0.00 | 0.00 |
| Interest Coverage | -8.75 | -2,746.22 | -9,302.31 | -1,810.25 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 43.17 | 78.17 |
| Cash Conversion Cycle | 0.00 | 0.00 | 308.42 | 176.75 |